SYNTHESIS OF THERAPEUTIC PEPTIDES VIA MICROBIAL FERMENTATION WITH RECOMBINANT DNA-TECHNOLOGY

In just the last 5 years, the FDA has approved no fewer than 14 peptides with therapeutic activities. Today, there are around 70 therapeutic peptides under development in the pharmaceutical industry ─ of which an impressive 15 are in phase 3 ─ in many of the therapeutic areas which undergo the most intensive research and development, including oncology, diabetes, and cardiovascular and auto-immune diseases.

Peptides are an extremely promising area of pharmacological research, partly because their chemical synthesis cycle offers important advantages for the industry: a short production cycle and development times, easily scalable production for short peptides.

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Title

Job Level

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.